Category: Chronic Lymphocytic Leukemia

Tirabrutinib is a Selective BTK Inhibitor

The BTK kinases comprise 5 structural domains, including pleckstrin homology, TEC homology, Src homology, Src homology, and kinase domains. The activation of BTK kinase depends on recruitment to the plasma membrane via the pleckstrin homology domain. In humans, BTK mutations result in arrested B-cell development. Besides, it leads to...

Flavopiridol (Alvocidib) is a pan CDK Inhibitor

The cyclin-dependent kinases (CDKs) are serine/threonine protein kinases. And it exhibits drives force behind the cell cycle and cell proliferation. CDKs contain at least a catalytic subunit (CDK) and a regulatory subunit (cyclin). To date, at least 10 CDKs and 15 cyclins have been identified. Once activation, CDKs phosphorylate...

Ruxolitinib (INCB018424) is an Orally Active JAK1 and JAK2 Inhibitor

The myeloproliferative neoplasms (MPNs) are a group of related clonal diseases probably arising from hematopoietic progenitor or stem cells. Patients with MPNs have an increased risk of thrombotic and bleeding complications and disease progression to acute myeloid leukemia. JAK2 is a member of the JAK family of cytoplasmic tyrosine...

WZ811 is an Orally Active CXCR4 Antagonist

The C-X-C chemokine receptor-4 (CXCR4) is a seven-transmembrane G-protein coupled receptor (GPCR). It is a member of the family I GPCR or rhodopsin-like GPCR family. The chemokine stromal cell-derived factor-1 (SDF-1 or CXCL12) is a CXC chemokine peptide. Meanwhile, it is the natural ligand for CXCR4. Importantly, the CXCR4...

NXT629 is a Selective and Competitive PPARα Antagonist

Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors that belong to the nuclear hormone receptor superfamily. Of these, PPARα mainly expresses in the liver, where it activates fatty acid catabolism. PPARδ expresses ubiquitously and implicates in fatty acid oxidation and keratinocyte differentiation. PPARγ2 expresses exclusively in adipose tissue and...

TAK-659 is a Dual SYK and FLT-3 Kinase Inhibitor for Leukemia Treatment

Acute Myelogenous Leukemia (AML) is a disease driven by SYK and/or FLT3-mediated signaling. In particular, spleen tyrosine kinase (SYK) is a 72 kD non-receptor cytoplasmic tyrosine kinase. SYK is a key mediator for a variety of inflammatory cells and immunology signaling pathways, including B cell receptor in B cells,...